Our current portfolio includes Sitavig^® and Loramyc^®, 2 products approved by FDA (Food and Drug Administration) and several authorities in Europe and 1 proprietary innovative galenic technology : Lauriad^®. Loramyc^® is available in the US, Italy and France. Sitavig^® is available in the US and has been launched in September 2018 in France. Vectans Pharma is the Marketing Authorization Holder (MAH) in the majority of european markets. Vectans Pharma concluded international licensing agreements in Europe, the US, Latin America and Asia, allowing distribution of Sitavig^® and Loramyc^®.